Takeda Ventures was among the investors as the cellular therapeutics developer launched with a round co-led by RA Capital Management and Atlas Venture.
US-based cellular medicine developer Be Biopharma has emerged from stealth with $52m in series A funding from investors including Takeda Ventures, the corporate venturing arm of pharmaceutical firm Takeda.
Venture capital firm Atlas Venture and investment management firm RA Capital Management co-led the round, which also featured VC firms Alta Partners and Longwood Fund.
Founded by Longwood Fund, Be Bio is engineering B cells collected from peripheral blood that possess qualities such as high protein production and precise tissue targeting,…
